

EMA/399748/2016

European Medicines Agency decision

P/0195/2016

of 15 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate) (QVM149), (EMA-001812-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0195/2016

of 15 July 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate) (QVM149), (EMA-001812-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Novartis Europharm Ltd. on 10 August 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 May 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate) (QVM149), inhalation powder, hard capsule, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate) (QVM149), inhalation powder, hard capsule, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for indacaterol (acetate) / glycopyrronium (bromide) / mometasone (furoate) (QVM149), inhalation powder, hard capsule, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Ltd., Frimley Business Park, GU16 7SR –Camberley, United Kingdom

Done at London, 15 July 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/192484/2016

London, 27 May 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001812-PIP01-15

Scope of the application

Active substance(s):

Indacaterol (acetate) / Glycopyrronium (bromide) / Mometasone (furoate) (QVM149)

Condition(s):

Treatment of asthma

Pharmaceutical form(s):

Inhalation powder, hard capsule

Route(s) of administration:

Inhalation use

Name / corporate name of the PIP applicant:

Novartis Europharm Ltd.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd. submitted for agreement to the European Medicines Agency on 10 August 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 15 September 2015.

Supplementary information was provided by the applicant on 7 March 2016.

The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of asthma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 6 years of age;
- for inhalation powder, hard capsule, inhalation use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of asthma

2.1.1. Indication(s) targeted by the PIP

Treatment of asthma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Inhalation powder, hard capsule

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable

Area	Number of measures	Description
Clinical studies	3	Study 1: Double-blind, randomised, parallel-group active controlled study to evaluate the efficacy and safety of QVM149 in children from 12 to less than 18 years of age with asthma Study 2: Double-blind, randomised, multiple dose, parallel-group, placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety and tolerability of glycopyrronium (bromide) in children from 6 to less than 12 years of age with asthma. Study 3: Double-blind, randomised, parallel-group active controlled study to evaluate the efficacy and safety of QVM149 in children from 6 to less than 12 years of age with asthma.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes